BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
30.92 USD +0.19% Intraday chart for BridgeBio Pharma, Inc. +6.69% -23.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating MT
BridgeBio Pharma Prices $250 Million Stock Offering MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
BridgeBio Pharma Commences $250 Million Share Offering MT
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating MT
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million MT
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe RE
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM CI
Citigroup Adjusts BridgeBio Pharma Price Target to $46 From $42, Maintains Buy Rating MT
Citigroup Adjusts Price Target on BridgeBio Pharma to $46 From $42, Keeps Buy Rating MT
BridgeBio Pharma Q4 Loss Widens as Revenue Declines MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q4 Revenue $1.7M MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
KKR to acquire a stake in health tech firm Cotiviti RE
BridgeBio Pharma Unit to Grant Kyowa Kirin License for Infigratinib in Japan MT
Bridgebio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan CI
BridgeBio Pharma Says US FDA Accepts New-Drug Application for Transthyretin Amyloid Cardiomyopathy Treatment MT
BridgeBio Pharma Gets FDA Acceptance for NDA of Acoramidis DJ
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy CI
AstraZeneca Says Phase 3 Trial of Acoramidis in Japan Well-Tolerated; Shows Consistency With Global Trial MT
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months CI
AstraZeneca: positive trial in cardiac amyloidosis CF
Chart BridgeBio Pharma, Inc.
More charts
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
30.92 USD
Average target price
49.38 USD
Spread / Average Target
+59.72%
Consensus
  1. Stock
  2. Equities
  3. Stock BridgeBio Pharma, Inc. - Nasdaq
  4. News BridgeBio Pharma, Inc.
  5. BridgeBio Pharma Sells Priority Review Right for Treatment of Rare Pediatric Disease for $110 Million